Does the degree of cell lesion in breast cancer after inductive chemotherapy have any prognostic value?

被引:5
作者
Tomczykowski, J
Szubstarski, F
Kurylcio, L
Stanislawek, A
Barycki, J
Baranowski, W [1 ]
机构
[1] Lublin Oncol Hosp, Dept Radiotherapy & Oncol Surg, Lublin, Poland
[2] Inst Agr Med, Lublin, Poland
[3] Tech Univ Lublin, Sch Med, Dept Gynaecol Surg, PL-20618 Lublin, Poland
关键词
D O I
10.1080/028418699432644
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
During 1991 and 1992, 77 patients with breast cancer were treated with induction chemotherapy using the CMFV and FAC protocols at the Lublin Oncological Centre. The degree of cancer cell damage in the specimens obtained postoperatively was evaluated by microscopy, Complete or substantial damage of neoplastic cells was found in 29%: of the cases, whereas minimal to no damage aas found in 71% of specimens. After assessing the 5-year survival periods of our patients in relation to the degree of cancer cell damage after induction chemotherapy, a statistically significant correlation was noted, Five-year survival without cancer symptoms was observed in 64% of eases in which the cell damage was estimated as considerable, and only in 34% in which the damage was slight or not notable. A much weaker correlation was observed between the degree of breast cancer cell damage after inductive chemotherapy and clinical response.
引用
收藏
页码:949 / 953
页数:5
相关论文
共 15 条
[1]   NEOADJUVANT CHEMOTHERAPY IN 126 OPERABLE BREAST CANCERS [J].
BELEMBAOGO, E ;
FEILLEL, V ;
CHOLLET, P ;
CURE, H ;
VERRELLE, P ;
KWIATKOWSKI, F ;
ACHARD, JL ;
LEBOUEDEC, G ;
CHASSAGNE, J ;
BIGNON, YJ ;
DELATOUR, M ;
LAFAYE, C ;
DAUPLAT, J .
EUROPEAN JOURNAL OF CANCER, 1992, 28A (4-5) :896-900
[2]   HISTOLOGICAL GRADING AND PROGNOSIS IN BREAST CANCER - A STUDY OF 1409 CASES OF WHICH 359 HAVE BEEN FOLLOWED FOR 15 YEARS [J].
BLOOM, HJG ;
RICHARDSON, WW .
BRITISH JOURNAL OF CANCER, 1957, 11 (03) :359-&
[3]  
BONADONNA G, 1991, SEMIN ONCOL, V18, P515
[4]   Long-term prognostic and predictive factors in 107 stage II/III breast cancer patients treated with anthracycline-based neoadjuvant chemotherapy [J].
Brain, E ;
Garrino, C ;
Misset, JL ;
Carbonero, IG ;
Itzhaki, M ;
Cvitkovic, E ;
Goldschmidt, E ;
Burki, F ;
Regensberg, C ;
Pappo, E ;
Hagipantelli, R ;
Musset, M .
BRITISH JOURNAL OF CANCER, 1997, 75 (09) :1360-1367
[5]   INFLAMMATORY BREAST-CANCER - PILOT-STUDY OF INTENSIVE INDUCTION CHEMOTHERAPY (FEC-HD) RESULTS IN A HIGH HISTOLOGIC RESPONSE RATE [J].
CHEVALLIER, B ;
ROCHE, H ;
OLIVIER, JP ;
CHOLLET, P ;
HURTELOUP, P .
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1993, 16 (03) :223-228
[6]  
CHEVALLIER B, 1990, P AN M AM SOC CLIN, V9, P42
[7]   Clinical and pathological response to primary chemotherapy in operable breast cancer [J].
Chollet, P ;
Charrier, S ;
Brain, E ;
Cure, H ;
vanPraagh, I ;
Feillel, V ;
deLatour, M ;
Dauplat, J ;
Misset, JL ;
Ferriere, JP .
EUROPEAN JOURNAL OF CANCER, 1997, 33 (06) :862-866
[8]   Induction chemotherapy with cisplatin, doxorubicin, and cyclophosphamide (CAP) in a combined modality approach for locally advanced and inflammatory breast cancer - Long-term results [J].
Colozza, M ;
Gori, S ;
Mosconi, AM ;
Anastasi, P ;
DeAngelis, V ;
Giansanti, M ;
Mercati, U ;
Aristei, C ;
Latini, P ;
Tonato, M .
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1996, 19 (01) :10-17
[9]  
FELDMAN LD, 1986, CANCER RES, V46, P2578
[10]  
Ferrero JM, 1997, B CANCER, V84, P10